Long-Term Survival Benefit with Durvalumab in NSCLC Confirmed in Updated Findings
June 4th 2021Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.
Read More
Frontline Nivolumab Plus Ipilimumab Show Long-Term Benefit in mNSCLC
June 4th 2021After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
Read More
Mobocertinib Induces Anticancer Responses in Platinum-Pretreated EGFR 20 Insertion+ Advanced NSCLC
June 4th 2021Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.
Read More
Tucatinib Concentrations Measured in CSF of Patients With HER2+ Metastatic Breast Cancer
June 4th 2021In a pharmacokinetic analysis of the first 15 patients in the phase 2 TBCRC049 study, researchers saw the first evidence for concentrations of tucatinib and ONT-993 in the cerebral spinal fluid of patients with HER2+ metastatic breast cancer with newly diagnosed leptomeningeal metastasis.
Read More
Investigational PSMA-Targeted Treatment Demonstrates Antitumor Activity in mCRPC
June 4th 2021In patients with metastatic castration-resistant prostate cancer treated in a phase 1/2a study, the HPN424, a tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager was well tolerated and demonstrated antitumor activity.
Read More
Cilta-Cel Elicits Deep Response Early On in Patients With R/R Multiple Myeloma
June 4th 2021One infusion of ciltacabtagene autoleucel lead to early and deep responses in a cohort of patients previously treated for relapsed/refractory multiple myeloma, according to findings the phase 2 CARTITUDE-2 study.
Read More
Pralsentinib Demonstrates Tolerability and Elicits Durable Responses in RET Fusion-Positive NSCLC
June 4th 2021In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.
Read More
In Some Heavily Pretreated Patients with R/R MM Ide-Cel Continues to Show Deep and Durable Responses
June 4th 2021Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor T-cell therapy, idecabtagene vicleucel, continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More
Increased Dose of Ripretinib Improves Survival in Heavily Pretreated Advanced GIST
June 4th 2021Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.
Read More
Niraparib Maintenance Prolongs PFS in BRCA-Positive Ovarian Cancer
June 4th 2021In patients with ovarian cancer and BRCA mutations who were enrolled in 3 different trials, maintenance treatment with niraparib improved progression-free survival compared with placebo with no new safety signals.
Read More
Adjuvant Chemotherapy Does Not Improve 5-Year Overall Survival in Locally Advanced Cervical Cancer
June 3rd 2021In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.
Read More
Adjuvant Pembrolizumab Significantly Reduces Risk of Disease Recurrence or Death in RCC
June 3rd 2021Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.
Read More
Lower Medicaid Eligibility May Equate to Worse Cancer Survival Rates
May 19th 2021Policies may be needed to expand Medicaid access to patients, after investigators found worse long-term survival outcomes for patients who lived in states with lower income eligibility rather than higher income eligibility.
Read More
Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone
April 13th 2021For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.
Read More
Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC
April 13th 2021Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.
Read More
HER2-Expressing Gastric Cancer Cells Respond to Treatment With Trastuzumab Deruxtecan
April 10th 2021For the treatment of patients with HER2-amplified gastric cancers in addition to those with HER2 moderate-, low-, and non-expressing disease, trastuzumab deruxtecan has shown to be an effective therapeutic option.
Read More
Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors
April 10th 2021In NRG1 fusion–positive cell lines, zenocutuzumab demonstrated blockage of growth and cell death, as well as tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.
Read More